24th Dec 2009 07:01
MedImmune Replies to FDA Complete Response Letter on Motavizumab
AstraZeneca today announced that MedImmune, its biologics unit, has filed its formal regulatory reply to a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA). MedImmune received the CRL asking for additional information regarding motavizumab on 25 November 2008, and the company has been in ongoing discussions with FDA reviewers since then to complete and file its CRL reply.
The CRL is in connection with the Biologics License Application (BLA) for motavizumab for the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants, which was submitted on 30 January 2008. Motavizumab is an investigational monoclonal antibody (MAb) with enhanced activity against RSV compared to Synagis (palivizumab).MedImmune was not required to conduct additional clinical trials in responding to the CRL. MedImmune will continue discussions with the FDA reviewers as needed throughout the remainder of the registration process.
About AstraZenecaAstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com
About MedImmuneMedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.
|
Media Enquiries UK: |
||
|
Neil McCrae |
+44 20 7304 5045 (24 hours) |
|
|
Chris Sampson |
+44 20 7304 5130 (24 hours) |
|
|
Sarah Lindgreen |
+44 20 7304 5033 (24 hours) |
|
|
Abigail Baron |
+44 20 7304 5034 (24 hours) |
|
|
Investor Enquiries UK: |
||
|
Jonathan Hunt |
+44 207 304 5087 |
mob: +44 7775 704032 |
|
Karl Hård |
+44 207 304 5322 |
mob: +44 7789 654364 |
|
Clive Morris |
+44 207 304 5084 |
mob: +44 7710 031012 |
|
Investor Enquiries US: |
||
|
Ed Seage |
+1 302 886 4065 |
mob: +1 302 373 1361 |
|
Jorgen Winroth |
+1 212 579 0506 |
mob: +1 917 612 4043 |
Related Shares:
Astrazeneca